Landmark trials in the medical oncology management of early stage breast cancer

Whitney Hensing, Cesar A. Santa-Maria, Lindsay L. Peterson, Jennifer Y. Sheng

Research output: Contribution to journalReview articlepeer-review

Abstract

With the advent of breast cancer screening programs, the majorities of patients with newly diagnosed breast cancer are diagnosed with early stage disease and are likely to experience cure with proper treatment. Significant advances have been made in the management of early-stage breast cancer to personalize treatment according to disease biology. This progress has led to improvement in survival outcomes and quality of life for our patients. In this review, we discuss landmark clinical trials in medical oncology that have shaped the current standard of care for early stage ER-positive, HER2-positive, and triple negative breast cancer.

Original languageEnglish (US)
Pages (from-to)278-292
Number of pages15
JournalSeminars in oncology
Volume47
Issue number5
DOIs
StatePublished - Oct 2020

Keywords

  • Adjuvant
  • Breast cancer
  • Clinical trials
  • HER-2
  • Hormone receptor
  • Neoadjuvant trastuzumab
  • Pertuzumab
  • T-DM1
  • Trastuzumab emtansine
  • Triple negative

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Landmark trials in the medical oncology management of early stage breast cancer'. Together they form a unique fingerprint.

Cite this